TrialCurvePERSEPHONE: reconstructed Kaplan–Meier curves
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Lancet. 2019 Jun 29;393(10191):2599–612. doi: 10.1016/S0140-6736(19)30650-6 |
|---|---|
| DOI | 10.1016/S0140-6736(19)30650-6 |
| Registry | NCT00712140 |
| Phase | Phase 3 |
| Conditions | Breast Cancer |
| Interventions | trastuzumab, parenteral chemotherapy |
| Sponsor | Warwick Medical School |
| Enrolment | 4000 |
| Source licence | Figure published under CC BY 4.0 |
Disease-free survival
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 12 months not reached; 6 months not reached. Survival at 2 years: 12 months 97%; 6 months 96%. Hazard ratio 12 months vs 6 months 0.92 (95% CI 0.76–1.11).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 12 months | 2045 | 203 | not reached |
| 6 months | 2043 | 221 | not reached |
- 12 months vs 6 months: reconstructed HR 0.92 (95% CI 0.76–1.11)
Landmark survival (reconstructed)
| Time | 12 months | 6 months |
|---|---|---|
| 1 yr | 100.0% | 99.4% |
| 2 yr | 96.6% | 95.6% |
| 3 yr | 92.9% | 91.5% |
| 5 yr | 88.6% | 87.7% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.07, reconstructed 1.09 pass
Overall survival
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 12 months not reached; 6 months not reached. Survival at 1 years: 12 months 100%; 6 months 100%. Hazard ratio 6 months vs 12 months 1.15 (95% CI 0.90–1.47).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 12 months | 2045 | 119 | not reached |
| 6 months | 2043 | 137 | not reached |
- 6 months vs 12 months: reconstructed HR 1.15 (95% CI 0.90–1.47)
Landmark survival (reconstructed)
| Time | 12 months | 6 months |
|---|---|---|
| 1 yr | 100.0% | 99.7% |
| 2 yr | 99.5% | 98.8% |
| 3 yr | 97.1% | 96.1% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.14, reconstructed 1.15 pass
Disease-free survival — Landmark analysis from 6 months after starting trastuzumab
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 12 months not reached; 6 months not reached. Survival at 1 years: 12 months 97%; 6 months 96%. Hazard ratio 6 months vs 12 months 1.06 (95% CI 0.88–1.28).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 12 months | 2009 | 211 | not reached |
| 6 months | 2000 | 229 | not reached |
- 6 months vs 12 months: reconstructed HR 1.06 (95% CI 0.88–1.28)
Landmark survival (reconstructed)
| Time | 12 months | 6 months |
|---|---|---|
| 1 yr | 97.0% | 96.4% |
| 2 yr | 93.4% | 92.5% |
| 3 yr | 90.9% | 89.9% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.07, reconstructed 1.06 pass
Overall survival — Landmark analysis from 6 months after starting trastuzumab
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 12 months not reached; 6 months not reached. Survival at 1 years: 12 months 100%; 6 months 99%. Hazard ratio 12 months vs 6 months 0.88 (95% CI 0.69–1.12).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 12 months | 2009 | 123 | not reached |
| 6 months | 2000 | 140 | not reached |
- 12 months vs 6 months: reconstructed HR 0.88 (95% CI 0.69–1.12)
Landmark survival (reconstructed)
| Time | 12 months | 6 months |
|---|---|---|
| 1 yr | 100.0% | 99.5% |
| 2 yr | 97.5% | 96.6% |
| 3 yr | 95.6% | 94.5% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.13, reconstructed 1.14 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/persephone-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/persephone-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Lancet. 2019 Jun 29;393(10191):2599–612. doi: 10.1016/S0140-6736(19)30650-6 doi:10.1016/S0140-6736(19)30650-6. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/persephone
Report a problem with these data
Related trials
- PEONY: Disease-free survival (DFS); Event-free survival (EFS)
- ACE-Breast-02: Overall survival; Progression-free survival assessed by BICR; Progression-free survival as
- SECRAB: Disease free survival; Local recurrence; Loco-regional in-field recurrence; Overall surviv
- PANTHER: Breast cancer recurrence-free survival events (cumulative incidence)
- NK105 vs paclitaxel in metastatic breast cancer: Overall survival; Progression-free survival
- TROIKA (final analysis): Event free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials